Navigation Links
Hillenbrand, Inc. Declares First Quarterly Dividend As a New Publicly Traded Company

BATESVILLE, Ind., April 30 /PRNewswire-FirstCall/ -- Hillenbrand, Inc. (NYSE: HI) today announced that its Board of Directors declared the company's first dividend as a publicly traded company of $0.1825 per share on the company's common stock. The dividend is payable June 30, 2008 to shareholders of record at the close of business on June 16, 2008.

"The decision by our board to approve this inaugural dividend is based on the strength of our fundamentals, including strong and consistent cashflows, and demonstrates our long-term commitment to creating and increasing shareholder value," said Hillenbrand's President and CEO, Kenneth A. Camp.


Hillenbrand, Inc. is the holding company for Batesville Casket Company, a leader in the North American death care industry through the sale of funeral services products, including burial caskets, cremation caskets, containers and urns, selection room display fixturing and other personalization and memorialization products.

Batesville Casket Company ... helping families honor the lives of those they love.

Certain statements in this release contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, regarding the future plans, objectives, beliefs, expectations, representations, and projections of Hillenbrand, Inc. (the "Company"). The Company has tried, wherever possible, to identify these forward looking statements using words such as "intend," "anticipate," "believe," "plan," "expect," "may," "goal," "become," "pursue," "estimate," "strategy," "will," "projection," "forecast," "continue," "accelerate," "promise," "increase," "higher," "lower," "reduce," "improve," "expand," "progress," "potential" or the negative of those terms, other variations of them, or by comparable terminology. The absence of such terms, however, does not mean that the statement is not forward looking. It is important to note that forward looking statements are not guarantees of future performance, and the Company's actual results could differ materially from those set forth in any forward looking statements. Factors that could cause actual results to differ from forward looking statements include, but are not limited to: the antitrust litigation in which the Company is currently a defendant; the Company's dependence on its relationships with several large national providers; continued fluctuations in mortality rates and increased cremations; ongoing involvement in claims, lawsuits, and governmental proceedings; failure of the Company's announced strategic initiatives to achieve expected growth, efficiencies, or cost reductions; disruptions in the Company's business or other adverse consequences resulting from the spin-off of the Company from Hillenbrand Industries, Inc.; competition from nontraditional sources in the funeral service business; increased costs or unavailability of raw materials; labor disruptions; the ability to retain executive officers and other key personnel; and certain tax-related matters. For a more in depth discussion of these and other factors that could cause actual results to differ from those contained in forward looking statements, see the discussions under the heading "Risk Factors" in the Information Statement dated March 17, 2008 filed as Exhibit 99.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 17, 2008. The Company assumes no obligation to update or revise any forward looking statements.

SOURCE Hillenbrand, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Torchmark Corporation Declares Dividend
3. Aflac Incorporated Announces First Quarter Results, Declares Second Quarter Cash Dividend
4. STERIS Corporation Declares Regular Quarterly Dividend
5. State Legislature Declares April 21 to 25, 2008 West Nile Virus and Mosquito and Vector Control Awareness Week
6. Lilly Declares Second-Quarter Dividend
7. Otter Tail Corporation Holds 2008 Annual Meeting: Shareholders Elect Directors; Board Declares Quarterly Dividend
8. NCPA Declares April 14 - 18 Protect Your Pharmacy Week
9. P&G Declares a 14% Dividend Increase
10. Coalition to Prevent Deep-Vein Thrombosis (DVT) Turns Awareness Into Action as it Declares First-Of-Its-Kind National DVT Screening Day
11. Birner Dental Management Services, Inc. Declares $.17 Quarterly Dividend
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ -- ... of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays ... film for accurate interpretation by the radiologist. The marking utensils are so small, ... Calif., has found a way to alleviate this problem. , He developed the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... Burlington, MA (PRWEB) , ... December 01, 2015 , ... ... the release of Clarity, the latest addition to the devices for sale in the ... technologies, 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - CES, Las Vegas, ... Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, where they will ... Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... ) has announced the addition of ... Testing Market: Campylobacter, Cryptosporidium, E. Coli, ... Yersinia" report to their offering. ... announced the addition of the ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... --  Craneware, Inc ., the healthcare market leader ... company will showcase a new version of its ... at the American Society for Health-System Pharmacists (ASHP) ... features are focused on simplifying and streamlining the ... pharmacy charges to ensure compliance and optimal revenue ...
Breaking Medicine Technology: